Frontiers in Oncology (Aug 2021)
Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
- Yuan Ding,
- Yuan Ding,
- Yuan Ding,
- Yuan Ding,
- Yuan Ding,
- Yuan Ding,
- Xin Han,
- Xin Han,
- Xin Han,
- Xin Han,
- Xin Han,
- Xin Han,
- Zhongquan Sun,
- Zhongquan Sun,
- Zhongquan Sun,
- Zhongquan Sun,
- Zhongquan Sun,
- Zhongquan Sun,
- Jinlong Tang,
- Yingsheng Wu,
- Yingsheng Wu,
- Yingsheng Wu,
- Yingsheng Wu,
- Yingsheng Wu,
- Yingsheng Wu,
- Weilin Wang,
- Weilin Wang,
- Weilin Wang,
- Weilin Wang,
- Weilin Wang,
- Weilin Wang
Affiliations
- Yuan Ding
- Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Yuan Ding
- Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province , Hangzhou, China
- Yuan Ding
- Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, China
- Yuan Ding
- Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China
- Yuan Ding
- Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province , Hangzhou, China
- Yuan Ding
- Zhejiang University Cancer Center, Hangzhou, China
- Xin Han
- Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Xin Han
- Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province , Hangzhou, China
- Xin Han
- Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, China
- Xin Han
- Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China
- Xin Han
- Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province , Hangzhou, China
- Xin Han
- Zhejiang University Cancer Center, Hangzhou, China
- Zhongquan Sun
- Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Zhongquan Sun
- Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province , Hangzhou, China
- Zhongquan Sun
- Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, China
- Zhongquan Sun
- Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China
- Zhongquan Sun
- Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province , Hangzhou, China
- Zhongquan Sun
- Zhejiang University Cancer Center, Hangzhou, China
- Jinlong Tang
- Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Yingsheng Wu
- Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Yingsheng Wu
- Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province , Hangzhou, China
- Yingsheng Wu
- Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, China
- Yingsheng Wu
- Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China
- Yingsheng Wu
- Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province , Hangzhou, China
- Yingsheng Wu
- Zhejiang University Cancer Center, Hangzhou, China
- Weilin Wang
- Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Weilin Wang
- Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province , Hangzhou, China
- Weilin Wang
- Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, China
- Weilin Wang
- Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China
- Weilin Wang
- Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province , Hangzhou, China
- Weilin Wang
- Zhejiang University Cancer Center, Hangzhou, China
- DOI
- https://doi.org/10.3389/fonc.2021.691380
- Journal volume & issue
-
Vol. 11
Abstract
Intrahepatic cholangiocarcinoma (CCA), always diagnosed at an advanced stage in recent years, is of high aggression and poor prognosis. There is no standard treatment beyond first-line chemotherapy and no molecular-targeted agents or immune checkpoint inhibitors approved for advanced intrahepatic CCA. Hence, we firstly report an original therapeutic strategy for a 60-year-old patient diagnosed with intrahepatic CCA categorized as Stage IIIB (T3N1M0) by the American Joint Committee on Cancer staging system. After histopathological examination and next-generation sequencing, the patient was treated with four courses of novel systemic sequential therapy (intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8; oral lenvatinib 8 mg/day from days 1 to 21; intravenous tislelizumab 200 mg on day 15). Then, the patient achieved partial response and was operated on right hemihepatectomy, cholecystectomy, and abdominal lymph node dissection. Without any perioperative complications, the patient was discharged from our hospital in perfect condition. Thereafter, the patient continued to use this new regimen 1 month after surgery for adjuvant therapy and was confirmed without recurrence when we followed up. In a word, we found an effective therapeutic regimen for preoperative advanced intrahepatic CCA conversion therapy, which may become a new approach in cancer treatment in the future.
Keywords
- advanced intrahepatic cholangiocarcinoma
- systemic sequential therapy
- surgery
- conversion therapy
- next-generation sequencing
